Regeneron Deal Clears Formycon’s Eylea Biosimilar for Late 2026

Formycon AG can launch its biosimilar version of Regeneron Pharmaceuticals Inc.’s blockbuster eye-disease drug Eylea in the fourth quarter of 2026 after the companies settled their US patent litigation.

The deal resolves all claims involving Formycon in consolidated litigation in the US District Court for the Northern District of West Virginia, according to a stipulation and order issued Monday dismissing the case and vacating a preliminary injunction. Chief Judge Thomas S. Kleeh also canceled a hearing that had been scheduled Monday on Formycon’s bid to dissolve the injunction.

Regeneron said in a Monday statement it would dismiss all its intellectual ...